The role of hepatokines in metabolism

Nature Reviews Endocrinology

Volumn 9, Issue 3, 2013, Pages 144-152

  Stefan, Norbert ^a   Häring, Hans Ulrich ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RELATED GROWTH FACTOR; CYTOKINE; FETUIN A; FIBROBLAST GROWTH FACTOR 21; GROWTH FACTOR; HEPATOKINE; LIPOPROTEIN; SELENOPROTEIN P; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CYTOKINE RELEASE; DIABETOGENESIS; DYSLIPIDEMIA; ENERGY BALANCE; ENERGY EXPENDITURE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LIPID LIVER LEVEL; LIPID METABOLISM; LIPOPROTEIN METABOLISM; LIVER METABOLISM; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SKELETAL MUSCLE;

ADIPOKINES; ADIPOSE TISSUE; ALPHA-2-HS-GLYCOPROTEIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FATTY LIVER; FEMALE; GLUCOSE; HUMANS; LIPID METABOLISM; LIVER; MALE; MUSCLE PROTEINS; MUSCLE, SKELETAL;

EID: 84875549943     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2012.258     Document Type: Review

References (120)

1. Finucane, M. M. et al. National, regional, and global trends in body-mass index since 1980: Systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 377, 557-567 (2011).
2. Hu, F. B. et al. Adiposity as compared with physical activity in predicting mortality among women. N. Engl. J. Med. 351, 2694-2703 (2004).
3. Pischon, T. et al. General and abdominal adiposity and risk of death in Europe. N. Engl. J. Med. 359, 2105-2120 (2008).
4. Zimmet, P., Alberti, K. G. & Shaw, J. Global and societal implications of the diabetes epidemic. Nature 414, 782-787 (2001).
5. Li, T. Y. et al. Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation 113, 499-506 (2006).
6. Després, J. P. & Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 444, 881-887 (2006).
7. Turer, A. T. & Scherer P. E. Adiponectin: Mechanistic insights and clinical implications. Diabetologia 55, 2319-2326 (2012).
8. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85-97 (2011).
9. Pedersen, B. K. & Febbraio, M. A. Muscles, exercise and obesity: Skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 8, 457-465 (2012).
10. Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806 (2001).
11. Olefsky, J. M. & Glass, C. K. Macrophages, inflammation, and insulin resistance. Annu. Rev. Physiol. 72, 219-246 (2010).
12. Fu, S., Watkins, S. M. & Hotamisligil, G. S. The role of endoplasmic reticulum in hepatic lipid homeostasis and stress signaling. Cell Metab. 15, 623-634 (2012).
13. Nolan, C. J., Damm, P. & Prentki, M. Type 2 diabetes across generations: From pathophysiology to prevention and management. Lancet 378, 169-181 (2011).
14. Kadowaki, T. et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116, 1784-1792 (2006).
15. Mitchell, F. Obesity: Glypican?4Role in insulin signalling. Nat. Rev. Endocrinol. 8, 505 (2012).
16. Hoene, M. & Weigert, C. The role of interleukin?6 in insulin resistance, body fat distribution and energy balance. Obes. Rev. 9, 20-29 (2008).
17. Boström, P. et al. A PGC1-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 481, 463-468 (2012).
18. Cunha, A. Basic research: Irisin - behind the benefits of exercise. Nat. Rev. Endocrinol. 8, 195 (2012).
19. Hoene, M. & Weigert, C. The stress response of the liver to physical exercise. Exerc. Immunol. Rev. 16, 163-183 (2010).
20. Stefan, N. et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J. Clin. Endocrinol. Metab. 92, 1827-1833 (2007).
21. Thamer, C. et al. Variations in PPARD determine the change in body composition during lifestyle intervention: A whole-body magnetic resonance study. J. Clin. Endocrinol. Metab. 93, 1497-1500 (2008).
22. Kacerovsky-Bielesz, G. et al. Short-term exercise training does not stimulate skeletal muscle ATP synthesis in relatives of humans with type 2 diabetes. Diabetes 58, 1333-1341 (2009).
23. Kantartzis, K. et al. High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut 58, 1281-1288 (2009).
24. Stefan, N. et al. Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 168, 1609-1616 (2008).
25. Fabbrini, E. et al. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl Acad. Sci. USA 106, 15430-15435 (2009).
26. Stefan, N., Kantartzis, K. & Häring, H. U. Causes and metabolic consequences of fatty liver. Endocr. Rev. 29, 939-960 (2008).
27. Roden, M. Mechanisms of disease: hepatic steatosis in type 2 diabetes - pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab. 2, 335-348 (2006).
28. Utzschneider, K. M. & Kahn, S. E. Review: The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91, 4753-4761 (2006).
29. Kotronen, A. & Yki-Jarvinen, H. Fatty liver: A novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 27-38 (2008).
30. Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341-1350 (2010).
31. Perseghin, G. Viewpoints on the way to a consensus session: where does insulin resistance start? The liver. Diabetes Care 32 (Suppl. 2), S164-S167 (2009).
32. Cusi, K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology 142, 711.e6-725.e6 (2012).
33. Gastaldelli, A. et al. Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects. Gastroenterology 133, 496-506 (2007).
34. Calori, G. et al. Fatty liver index and mortality: The Cremona study in the 15th year of follow-up. Hepatology 54, 145-152 (2011).
35. Roden, M. et al. Mechanism of free fatty acid-induced insulin resistance in humans. J. Clin. Invest. 97, 2859-2865 (1996).
36. Krssak, M. et al. Alterations in postprandial hepatic glycogen metabolism in type 2 diabetes. Diabetes 53, 3048-3056 (2004).
37. Roden, M. & Bernroider, E. Hepatic glucose metabolism in humans - its role in health and disease. Best Pract. Res. Clin. Endocrinol. Metab. 17, 365-383 (2003).
38. Ramnanan, C. J. et al. Brain insulin action augments hepatic glycogen synthesis without suppressing glucose production or gluconeogenesis in dogs. J. Clin. Invest. 121, 3713-3723 (2011).
39. Samuel, V. T., Petersen, K. F. & Shulman, G. I. Lipid-induced insulin resistance: Unravelling the mechanism. Lancet 375, 2267-2277 (2010).
40. Farese, R. V. Jr, Zechner, R., Newgard, C. B. & Walther, T. C. The problem of establishing relationships between hepatic steatosis and hepatic insulin resistance. Cell Metab. 15, 570-573 (2012).
41. Glass, C. K. & Olefsky, J. M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635-645 (2012).
42. Cohen, J. C., Horton, J. D. & Hobbs, H. H. Human fatty liver disease: Old questions and new insights. Science 332, 1519-1523 (2011).
43. Adiels, M., Olofsson, S. O., Taskinen, M. R. & Borén, J. Diabetic dyslipidaemia. Curr. Opin. Lipidol. 17, 238-246 (2006).
44. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
45. Cao, H. et al. Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134, 933-944 (2008).
46. Lautt, W. W. A proposed new paradigm for insulin resistance. Metab. Syndr. Relat. Disord. 1, 261-270 (2003).
47. Misu, H. et al. Genes involved in oxidative phosphorylation are coordinately upregulated with fasting hyperglycaemia in livers of patients with type 2 diabetes. Diabetologia 50, 268-277 (2007).
48. Cai, D. et al. Local and systemic insulin resistance resulting from hepatic activation of IKK and NFB. Nat. Med. 11, 183-190 (2005).
49. Oike, Y. et al. Angiopoietin-related growth factor antagonizes obesity and insulin resistance. Nat. Med. 11, 400-408 (2005).
50. Ebert, T. et al. Serum levels of angiopoietin-related growth factor in diabetes mellitus and chronic hemodialysis. Metabolism 58, 547-551 (2009).
51. Denecke, B. et al. Tissue distribution and activity testing suggest a similar but not identical function of fetuin?B and fetuin?A. Biochem. J. 376, 135-145 (2003).
52. Auberger, P. et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: CDNA cloning, purification, and anti-mitogenic activity. Cell 58, 631-640 (1989).
53. Rauth, G. et al. The nucleotide and partial amino acid sequences of rat fetuin. Identity with the natural tyrosine kinase inhibitor of the rat insulin receptor. Eur. J. Biochem. 204, 523-529 (1992).
54. Srinivas, P. R. et al. Serum ?2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol. Endocrinol. 7, 1445-1455 (1993).
55. Mathews, S. T. et al. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci. 61, 1583-1592 (1997).
56. Mathews, S. T. et al. ?2-HSG, a specific inhibitor of insulin receptor autophosphorylation, interacts with the insulin receptor. Mol. Cell. Endocrinol. 164, 87-98 (2000).
57. Goustin, A. S. & Abou-Samra, A. B. The "thrifty" gene encoding AHSG/Fetuin?A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signal. 23, 980-990 (2011).
58. Mathews, S. T. et al. Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes 51, 2450-2458 (2002).
59. Siddiq, A., Lepretre, F., Hercberg, S., Froguel, P. & Gibson, F. A synonymous coding polymorphism in the ?2-Heremans-Schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 54, 2477-2481 (2005).
60. Andersen, G. et al. AHSG tag single nucleotide polymorphisms associate with type 2 diabetes and dyslipidemia: Studies of metabolic traits in 7,683 white Danish subjects. Diabetes 57, 1427-1432 (2008).
61. Stefan, N. et al. ?2-Heremans-Schmid glycoprotein/fetuin?A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29, 853-857 (2006).
62. Reinehr, T. & Roth, C. L. Fetuin?A and its relation to metabolic syndrome and fatty liver disease in obese children before and after weight loss. J. Clin. Endocrinol. Metab. 93, 4479-4485 (2008).
63. Haukeland, J. W. et al. Fetuin A in nonalcoholic fatty liver disease: In vivo and in vitro studies. Eur. J. Endocrinol. 166, 503-510 (2012).
64. Dasgupta, S. et al. NFB mediates lipid-induced fetuin?A expression in hepatocytes that impairs adipocyte function effecting insulin resistance. Biochem. J. 429, 451-462 (2010).
65. Takata, H. et al. High glucose induces transactivation of the ?2-HS glycoprotein gene through the ERK1/2 signaling pathway. J. Atheroscler. Thromb. 16, 448-456 (2009).
66. Rittig, K. et al. High plasma fetuin?A is associated with increased carotid intima-media thickness in a middle-aged population. Atherosclerosis 207, 341-342 (2009).
67. Dogru, T. et al. Plasma fetuin?A is associated with endothelial dysfunction and subclinical atherosclerosis in subjects with nonalcoholic fatty liver disease. Clin. Endocrinol. (Oxf.) http://dx.doi.org/10.1111/j.1365?2265. 2012.04460.x.
68. Ix, J. H. et al. Association between human fetuin?A and the metabolic syndrome: Data from the Heart and Soul Study. Circulation 113, 1760-1767 (2006).
69. Mori, K. et al. Association of serum fetuin?A with insulin resistance in type 2 diabetic and nondiabetic subjects. Diabetes Care 29, 468 (2006).
70. Kantartzis, K. et al. The impact of liver fat vs visceral fat in determining categories of prediabetes. Diabetologia 53, 882-889 (2010).
71. Xu, Y. et al. Serum fetuin?A is correlated with metabolic syndrome in middle-aged and elderly Chinese. Atherosclerosis 216, 180-186 (2011).
72. Ishibashi, A. et al. Serum fetuin?A is an independent marker of insulin resistance in Japanese men. J. Atheroscler. Thromb. 17, 925-933 (2010).
73. Kaess, B. M. et al. Cardiometabolic correlates and heritability of fetuin?A, retinol-binding protein 4 and fatty-acid binding protein 4 in the Framingham Heart Study. J. Clin. Endocrinol. Metab. 97, E1943-E1947 (2012).
74. Stefan, N. et al. Plasma fetuin?A levels and the risk of type 2 diabetes. Diabetes 57, 2762-2767 (2008).
75. Ix, J. H. et al. Health ABC Study. Fetuin?A and incident diabetes mellitus in older persons. JAMA 300, 182-188 (2008).
76. Ix, J. H. et al. Association of fetuin?A with incident diabetes mellitus in community-living older adults: The cardiovascular health study. Circulation 125, 2316-2322 (2012).
77. Sun, Q., Cornelis, M. C., Manson, J. E. & Hu, F. B. Plasma levels of fetuin?A and hepatic enzymes and risk of type 2 diabetes in women in the U.S. Diabetes 62, 49-55 (2013).
78. Hennige, A. M. et al. Fetuin?A induces cytokine expression and suppresses adiponectin production. PLoS ONE 3, e1765 (2008).
79. Pal, D. et al. Fetuin?A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat. Med. http://dx.doi.org/10.1038/nm.2851.
80. Heinrichsdorff, J. & Olefsky, J. M. Fetuin?A: The missing link in lipid-induced inflammation. Nat. Med. 18, 1182-1183 (2012).
81. Weikert, C. et al. Plasma fetuin?A levels and the risk of myocardial infarction and ischemic stroke. Circulation 118, 2555-2562 (2008).
82. Fisher, E. et al. Association of AHSG gene polymorphisms with fetuin?A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ. Cardiovasc. Genet. 2, 607-613 (2009).
83. Kharitonenkov, A. et al. FGF?21 as a novel metabolic regulator. J. Clin. Invest. 115, 1627-1635 (2005).
84. Fon Tacer, K. et al. Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 24, 2050-2064 (2010).
85. Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250-259 (2009).
86. Potthoff, M. J., Kliewer, S. A. & Mangelsdorf, D. J. Endocrine fibroblast growth factors 15/19 and 21: From feast to famine. Genes Dev. 26, 312-324 (2012).
87. Jones, J. I. & Clemmons, D. R. Insulin-like growth factors and their binding proteins: Biological actions. Endocr. Rev. 16, 3-34 (1995).
88. Ohlsson, C. et al. The role of liver-derived insulin-like growth factor?I. Endocr. Rev. 30, 494-535 (2009).
89. Jogie-Brahim, S., Feldman, D. & Oh, Y. Unraveling insulin-like growth factor binding protein?3 actions in human disease. Endocr. Rev. 30, 417-437 (2009).
90. Boulware, S. D., Tamborlane, W. V., Rennert, N. J., Gesundheit, N. & Sherwin, R. S. Comparison of the metabolic effects of recombinant human insulin-like growth factor?I and insulin. Dose-response relationships in healthy young and middle-aged adults. J. Clin. Invest. 93, 1131-1139 (1994).
91. Moses, A. C., Young, S. C., Morrow, L. A., O'Brien, M. & Clemmons, D. R. Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45, 91-100 (1996).
92. Rajpathak, S. N. et al. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes 61, 2248-2254 (2012).
93. Arturi, F. et al. Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor?I. J. Clin. Endocrinol. Metab. 96, E1640-E1644 (2011).
94. Gawrieh, S. et al. Hepatic gene networks in morbidly obese patients with nonalcoholic fatty liver disease. Obes. Surg. 20, 1698-1709 (2010).
95. Misu, H. et al. A liver-derived secretory protein, selenoprotein P, causes insulin resistance. Cell Metab. 12, 483-495 (2010).
96. Yang, S. J. et al. Serum selenoprotein P levels in patients with type 2 diabetes and prediabetes: Implications for insulin resistance, inflammation, and atherosclerosis. J. Clin. Endocrinol. Metab. 96, E1325-E1329 (2011).
97. Misu, H. et al. Inverse correlation between serum levels of selenoprotein P and adiponectin in patients with type 2 diabetes. PLoS ONE 7, e34952 (2012).
98. Khan, M. S., Knowles. B. B., Aden, D. P. & Rosner, W. Secretion of testosterone-estradiol-binding globulin by a human hepatoma-derived cell line. J. Clin. Endocrinol. Metab. 53, 448-449 (1981).
99. Ding, E. L. et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N. Engl. J. Med. 361, 1152-1163 (2009).
100. Perry, J. R. et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum. Mol. Genet. 19, 535-544 (2010).
101. Sutton-Tyrrell, K. et al. Sex-hormone-binding globulin and the free androgen index are related to cardiovascular risk factors in multiethnic premenopausal and perimenopausal women enrolled in the Study of Women Across the Nation (SWAN). Circulation 111, 1242-1249 (2005).
102. Selva, D. M., Hogeveen, K. N., Innis, S. M. & Hammond, G. L. Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J. Clin. Invest. 117, 3979-3987 (2007).
103. Simó, R., Barbosa-Desongles, A., Lecube, A., Hernandez, C. & Selva, D. M. Potential role of tumor necrosis factor in downregulating sex hormone-binding globulin. Diabetes 61, 372-382 (2012).
104. Simó, R., Barbosa-Desongles, A., Hernandez, C. & Selva, D. M. IL1? down-regulation of sex hormone-binding globulin production by decreasing HNF?4? via MEK?1/2 and JNK MAPK pathways. Mol. Endocrinol. 26, 1917?1927 (2012).
105. Stefan, N., Schick, F. & Häring, H. U. Sex hormone-binding globulin and risk of type 2 diabetes. N. Engl. J. Med. 361, 2675-2676 (2009).
106. Vassilatou, E. et al. Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum. Reprod. 25, 212-220 (2010).
107. Peter, A. et al. Relationships of circulating sex hormone-binding globulin with metabolic traits in humans. Diabetes 59, 3167-3173 (2010).
108. Rosner, W. et al. Sex hormone-binding globulin. Binding to cell membranes and generation of a second messenger. J. Androl. 13, 101-106 (1992).
109. Kahn, S M, Hryb, D.J., Nakhla, A.M., Romas, N. A.,& Rosner, W. Sex hormone-binding globulin is synthesized in target cells. J. Endocrinol. 175, 113-120 (2002).
110. Rosner, W., Hryb, D. J., Khan, M. S., Nakhla, A. M. & Romas, N. A. Sex hormone-binding globulin mediates steroid hormone signal transduction at the plasma membrane. J. Steroid Biochem. Mol. Biol. 69, 481-485 (1999).
111. Le, T. N., Nestler J. E., Strauss, J. F. 3rd & Wickham, E. P. 3rd. Sex hormone-binding globulin and type 2 diabetes mellitus. Trends Endocrinol. Metab. 23, 32-40 (2012).
112. Chalasani, N. et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142, 1592-1609 (2012).
113. Bugianesi, E. Non-alcoholic steatohepatitis and cancer. Clin. Liver Dis. 11, 191-207 (2007).
114. Starley, B. Q., Calcagno, C. J. & Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 51, 1820-1832 (2010).
115. Targher, G., Day, C. P. & Bonora, E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341-1350 (2010).
116. Romeo, S. et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461-1465 (2008).
117. Kantartzis, K. et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58, 2616-2623 (2009).
118. Kotronen, A. et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52, 1056-1060 (2009).
119. Speliotes, E. K. et al. PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease. Hepatology 52, 904-912 (2010).
120. Stefan, N. & Häring, H. U. The metabolically benign and malignant fatty liver. Diabetes 60, 2011-2017 (2011).